公开(公告)号：US12139471B2

公开(公告)日：2024-11-12

申请号：US17574820

申请日：2022-01-13

Applicant: Novartis AG

Inventor： Christopher Farady ,  Nina Gommermann ,  Philipp Janser ,  Angela Mackay ,  Henri Mattes ,  Nichola Smith ,  Catherine Fooks Solovay ,  Nikolaus Johannes Stiefl ,  Eric Vangrevelinghe ,  Juraj Velcicky ,  Anette von Matt

IPC: C07D401/12 ,  C07D237/14 ,  C07D237/20 ,  C07D403/12 ,  C07D413/12 ,  C07D451/04

Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.

公开(公告)号：US11208399B2

公开(公告)日：2021-12-28

申请号：US16874862

申请日：2020-05-15

Applicant: Novartis AG

Inventor： Christopher Farady ,  Nina Gommermann ,  Philipp Janser ,  Angela Mackay ,  Henri Mattes ,  Nichola Smith ,  Catherine Fooks Solovay ,  Nikolaus Johannes Stiefl ,  Eric Vangrevelinghe ,  Juraj Velcicky ,  Anette von Matt

IPC: C07D401/12 ,  C07D237/14 ,  C07D237/20 ,  C07D403/12 ,  C07D413/12 ,  C07D451/04

Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.

公开(公告)号：US12168012B2

公开(公告)日：2024-12-17

申请号：US17259252

申请日：2019-07-23

Applicant: Novartis AG

Inventor： Christopher Farady ,  Nina Gommermann ,  Philipp Janser ,  Angela MacKay ,  Henri Mattes ,  Nikolaus Johannes Stiefl ,  Juraj Velcicky

IPC: A61K31/53 ,  A61K31/616 ,  A61K45/06 ,  C07D495/14 ,  C07D513/14 ,  C07D515/14

Abstract: The present invention relates to novel thienopyrrolotriazinacetamide compounds of Formula (I): wherein R1, R2 and R3 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.

公开(公告)号：US20230365571A1

公开(公告)日：2023-11-16

申请号：US18044455

申请日：2021-09-15

Applicant: Novartis AG

Inventor： Trixi Brandl ,  Claus Ehrhardt ,  Robert Epple ,  Christian Markert ,  Pascal Rigollier ,  Juraj Velcicky

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: The present invention relates to tricyclic compounds comprising a diazepinone moiety which are effective in inhibiting Sppl2a (signal peptide peptidase like protease 2a), to pharmaceutical compositions containing such inhibitors, and to methods of using such inhibitors and compositions.

公开(公告)号：US11254653B2

公开(公告)日：2022-02-22

申请号：US16874905

申请日：2020-05-15

Applicant: Novartis AG

Inventor： Christopher Farady ,  Nina Gommermann ,  Philipp Janser ,  Angela Mackay ,  Henri Mattes ,  Nichola Smith ,  Catherine Fooks Solovay ,  Nikolaus Johannes Stiefl ,  Eric Vangrevelinghe ,  Juraj Velcicky ,  Anette von Matt

IPC: C07D401/12 ,  C07D237/14 ,  C07D237/20 ,  C07D403/12 ,  C07D413/12 ,  C07D451/04

Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.